KPV Peptide Research:
Alpha-MSH Fragment & Anti-Inflammatory Biology
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH) that retains potent anti-inflammatory activity. It activates melanocortin receptors, suppresses NF-κB, and demonstrates barrier-protective effects in gut and skin research models.
What Is KPV?
KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal sequence (residues 11-13) of alpha-melanocyte stimulating hormone (α-MSH; α-MSH₁₋₁₃). While the full 13-residue α-MSH activates all melanocortin receptors (MC1R–MC4R), KPV retains primary activity at MC1R and to a lesser extent MC3R. Its minimal tripeptide structure confers favorable stability compared to the full-length peptide while preserving the key anti-inflammatory pharmacophore.
KPV has been studied extensively in gut inflammation models, skin biology, and barrier function research. It is notable for its ability to suppress NF-κB-driven inflammatory cascades in both immune cells and epithelial cells — making it a research tool for studying the intersection of melanocortin signaling and mucosal/cutaneous inflammation. Lumen Peppers provides research-grade KPV for in vitro and preclinical laboratory investigation only.
Key Research Findings
KPV research spans gut inflammation, skin barrier biology, NF-κB signaling, macrophage polarization, and wound healing models.
IBD & Colitis Models
KPV significantly reduces colon inflammation scores, TNF-α, IL-1β, and IL-6 in DSS-induced colitis mouse models. It reduces mucosal neutrophil infiltration and preserves tight junction protein expression (ZO-1, occludin), maintaining intestinal barrier integrity in inflamed tissue.
NF-κB Suppression in Epithelial Cells
KPV inhibits IκBα phosphorylation and NF-κB nuclear translocation in TNF-α- and LPS-stimulated intestinal epithelial cell lines (Caco-2, HT-29) at nanomolar concentrations. This transcriptional blockade reduces COX-2, iNOS, and inflammatory cytokine gene expression.
Skin Anti-Inflammatory Activity
In UV-irradiated keratinocyte models, KPV reduces NF-κB-driven pro-inflammatory gene expression and restores skin barrier protein expression. KPV also demonstrates anti-fibrotic activity in TGF-β1-stimulated dermal fibroblasts by modulating SMAD-pathway collagen overproduction.
Macrophage Polarization
KPV drives macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory/repair) phenotype. In LPS-stimulated RAW264.7 macrophages, KPV reduces TNF-α, IL-6, and IL-12 while increasing IL-10 and arginase-1 — markers of anti-inflammatory M2 activation.
Wound Healing Research
KPV accelerates keratinocyte migration in scratch assay models and reduces neutrophil-driven inflammatory phase duration in excisional wound models. Its dual MC1R agonism and NF-κB suppression provides a research tool for studying anti-inflammatory wound healing modulation.
Stable Tripeptide Pharmacology
KPV's tripeptide size provides research advantages over full α-MSH: greater proteolytic stability, simpler synthesis, reduced off-target receptor activity (minimal MC2R-ACTH axis engagement), and preserved anti-inflammatory pharmacophore. These properties make it a cleaner pharmacological tool for NF-κB/MC1R pathway studies.
Proposed Mechanisms of Action
KPV binds MC1R (Gs-coupled GPCR) on keratinocytes, macrophages, and intestinal epithelial cells, increasing intracellular cAMP via adenylyl cyclase. Elevated cAMP activates PKA, which phosphorylates IKKβ (IκB kinase β) — blocking IκBα ubiquitination and preventing NF-κB nuclear translocation.
By blocking IKKβ-mediated IκBα phosphorylation, KPV stabilizes the IκBα-NF-κB complex in the cytoplasm. This prevents transcription of NF-κB target genes including TNF-α, IL-1β, IL-6, IL-8, COX-2, and iNOS — the core inflammatory mediator panel suppressed by KPV in epithelial and immune cell models.
KPV also has partial activity at MC3R on immune cells (macrophages, dendritic cells). MC3R activation suppresses FcR-mediated phagocytosis and reduces pro-inflammatory cytokine secretion in myeloid cells — contributing to KPV's macrophage M1→M2 polarization effects alongside MC1R-cAMP signaling.
KPV upregulates tight junction protein expression (ZO-1, claudin-1, occludin) in intestinal epithelial cell models subjected to inflammatory challenge. This barrier-protective effect is partially NF-κB-mediated (NF-κB suppresses claudin-1 and ZO-1 expression) and partially via direct MC1R-MLCK axis modulation.
KPV activates Nrf2 (Nuclear factor erythroid 2-related factor 2) in keratinocytes and macrophages, upregulating antioxidant response element (ARE)-driven genes including NQO1, HMOX1, and glutathione S-transferase — contributing to its cytoprotective activity independent of the MC1R-NF-κB axis.
Active Research Applications
IBD & Gut Inflammation
DSS/TNBS colitis models, intestinal barrier permeability (TEER assays), and tight junction protein expression studies.
Skin Biology
UV-irradiated keratinocyte NF-κB studies, barrier gene expression, dermatitis models, and anti-fibrotic TGF-β1 studies.
NF-κB Pathway Studies
IκBα phosphorylation, nuclear p65 translocation, cytokine ELISA panels, and NF-κB reporter assays in epithelial/immune cells.
Macrophage Biology
M1/M2 polarization assays, cytokine profiling (IL-10, TNF-α, IL-12), and phagocytosis studies in LPS-stimulated macrophages.
Melanocortin Pharmacology
MC1R/MC3R binding studies, cAMP reporter assays, and structure-activity relationship (SAR) studies using KPV as a reference tripeptide.
Wound Healing Models
Scratch assays, excisional wound models, and inflammatory phase characterization studies using KPV to modulate early-phase inflammation.
Protocol Notes for Researchers
KPV Peptide — Research Grade ≥99%
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.